Nouscom AG

Our strategy stems from recent therapeutic achievements in the fields of checkpoint inhibitors, therapeutic antibodies, cancer vaccines and oncolytic viruses. We plan to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells. Our immunotherapeutics embody the best features of oncolytic viruses and therapeutic antibodies, and include viral vectored genetic vaccines based on patient- and tumor-specific antigens.